Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapeutic and palliative options for diffuse neuroendocrine metastatic disease.

× No keyword cloud information.

20 in total

1. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.

Authors: S M Ansell; H C Pitot; P A Burch; L K Kvols; M R Mahoney; J Rubin
Journal: Cancer Date: 2001-04-15 Impact factor: 6.860

Review 2. Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment.

Authors: K Oberg
Journal: Ann Oncol Date: 1999 Impact factor: 32.976

3. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors.

Authors: L Saltz; N Kemeny; G Schwartz; D Kelsen
Journal: Cancer Date: 1994-08-01 Impact factor: 6.860

4. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors.

Authors: Matthew H Kulke; Haesook Kim; Jeffrey W Clark; Peter C Enzinger; Thomas J Lynch; Jeffrey A Morgan; Michele Vincitore; Ann Michelini; Charles S Fuchs
Journal: Cancer Date: 2004-09-01 Impact factor: 6.860

5. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.

Authors: Siegbert Faiss; Ulrich-Frank Pape; Michael Böhmig; Yvonne Dörffel; Ulrich Mansmann; Werner Golder; Ernst Otto Riecken; Bertram Wiedenmann
Journal: J Clin Oncol Date: 2003-07-15 Impact factor: 44.544

Review 6. Gastrointestinal neuroendocrine tumors.

Authors: R Delcore; S R Friesen
Journal: J Am Coll Surg Date: 1994-02 Impact factor: 6.113

7. Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells.

Authors: Rebecca S Sippel; Jennifer E Carpenter; Muthusamy Kunnimalaiyaan; Sara Lagerholm; Herbert Chen
Journal: Am J Physiol Gastrointest Liver Physiol Date: 2003-08 Impact factor: 4.052

8. Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.

Authors: Andreas Kaubisch; Ron Kaleya; Hilda Haynes; Alla Rozenblit; Scott Wadler
Journal: Cancer Chemother Pharmacol Date: 2003-12-24 Impact factor: 3.333

9. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

Authors: C G Moertel; M Lefkopoulo; S Lipsitz; R G Hahn; D Klaassen
Journal: N Engl J Med Date: 1992-02-20 Impact factor: 91.245

Review 10. Islet cell tumors of the pancreas: the medical oncologist's perspective.

Authors: R Brentjens; L Saltz
Journal: Surg Clin North Am Date: 2001-06 Impact factor: 3.537

1 in total

1. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?

Authors: Ji-Shiang Hung; Ming-Chu Chang; Po-Huang Lee; Yu-Wen Tien
Journal: World J Surg Date: 2007-12 Impact factor: 3.282

1 in total